You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Pfizer moves higher after undertaking review of its respiratory portfolio

Capital Market 

rose 0.97% to Rs 1,828.40 at 12:42 on after the company said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 200.17 points or 0.76% at 26,550.34.

On BSE, so far 1,152 shares were traded in the counter as against average daily volume of 2,553 shares in the past one quarter. The stock hit a high of Rs 1,850 and a low of Rs 1,818 so far during the day. The stock had hit a 52-week high of Rs 2,540 on 7 December 2015. The stock had hit a 52-week low of Rs 1,611 on 21 March 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 0.64% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 7.04% as against the Sensex's 5.15% fall.

The mid-cap company has equity capital of Rs 45.75 crore. Face value per share is Rs 10.

said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg). said it stands by the safety and efficacy of its current Corex Cough Syrup formulation that has been duly approved by Central and State regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place, it added.

The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation, said.

Corex Cough Syrup recorded a sale of Rs 244.48 crore for the financial year ended 31 March 2016.

Pfizer's net profit rose 52.5% to Rs 126.33 crore on 4.9% growth in net sales to Rs 530.02 crore in Q2 September 2016 over Q2 September 2015.

is a leading biopharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Pfizer moves higher after undertaking review of its respiratory portfolio

Pfizer rose 0.97% to Rs 1,828.40 at 12:42 IST on BSE after the company said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications.

rose 0.97% to Rs 1,828.40 at 12:42 on after the company said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 200.17 points or 0.76% at 26,550.34.

On BSE, so far 1,152 shares were traded in the counter as against average daily volume of 2,553 shares in the past one quarter. The stock hit a high of Rs 1,850 and a low of Rs 1,818 so far during the day. The stock had hit a 52-week high of Rs 2,540 on 7 December 2015. The stock had hit a 52-week low of Rs 1,611 on 21 March 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 0.64% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 7.04% as against the Sensex's 5.15% fall.

The mid-cap company has equity capital of Rs 45.75 crore. Face value per share is Rs 10.

said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg). said it stands by the safety and efficacy of its current Corex Cough Syrup formulation that has been duly approved by Central and State regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place, it added.

The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation, said.

Corex Cough Syrup recorded a sale of Rs 244.48 crore for the financial year ended 31 March 2016.

Pfizer's net profit rose 52.5% to Rs 126.33 crore on 4.9% growth in net sales to Rs 530.02 crore in Q2 September 2016 over Q2 September 2015.

is a leading biopharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Pfizer moves higher after undertaking review of its respiratory portfolio

rose 0.97% to Rs 1,828.40 at 12:42 on after the company said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications.

The announcement was made after market hours yesterday, 28 November 2016.

Meanwhile, the S&P Sensex was up 200.17 points or 0.76% at 26,550.34.

On BSE, so far 1,152 shares were traded in the counter as against average daily volume of 2,553 shares in the past one quarter. The stock hit a high of Rs 1,850 and a low of Rs 1,818 so far during the day. The stock had hit a 52-week high of Rs 2,540 on 7 December 2015. The stock had hit a 52-week low of Rs 1,611 on 21 March 2016. The stock had outperformed the market over the past one month till 28 November 2016, sliding 0.64% compared with the Sensex's 5.7% fall. The scrip had, however, underperformed the market in past one quarter, declining 7.04% as against the Sensex's 5.15% fall.

The mid-cap company has equity capital of Rs 45.75 crore. Face value per share is Rs 10.

said it has undertaken a comprehensive review of its respiratory offerings in order to better cover a broader range of indications through an expanded product portfolio. As a result of this review, the company will launch additional products while it may also discontinue the manufacture of certain SKUs where needed. The company will be launching a series of products as line extensions under the Corex brand name, starting with the first launch in December 2016 and subsequent launches over the next year. The company has also decided to discontinue the manufacturing of the current Corex Cough Syrup formulation (Codeine Phosphate 10mg + Chlorpheniramine Maleate 4mg). said it stands by the safety and efficacy of its current Corex Cough Syrup formulation that has been duly approved by Central and State regulators. As with this formulation, all additional line extensions will be introduced with all due regulatory approvals in place, it added.

The company remains committed to providing a more comprehensive set of solutions in respiratory indications, while ensuring minimal impact towards patients resulting from the discontinuation of manufacturing of the current Corex Cough Syrup formulation, said.

Corex Cough Syrup recorded a sale of Rs 244.48 crore for the financial year ended 31 March 2016.

Pfizer's net profit rose 52.5% to Rs 126.33 crore on 4.9% growth in net sales to Rs 530.02 crore in Q2 September 2016 over Q2 September 2015.

is a leading biopharmaceutical company.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard